Karen Murphy Santiago's most recent trade in Catalent Inc. was a trade of 5,216 Options to purchase Common Stock done . Disclosure was reported to the exchange on Aug. 1, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Catalent Inc. | Karen Murphy Santiago | VP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2023 | 5,216 | 5,216 | - | - | Options to purchase Common Stock | |
| Catalent Inc. | Karen Murphy Santiago | VP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2023 | 2,342 | 4,763 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | Karen Murphy Santiago | VP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 3,030 | 3,030 | - | - | Options to purchase Common Stock | |
| Catalent Inc. | Karen Murphy Santiago | VP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 1,681 | 2,421 (0%) | 0% | 0 | Common Stock | |
| Catalent Inc. | Karen Murphy Santiago | VP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Sep 2022 | 740 | 740 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Sale of securities on an exchange or to another person at price $ 69.20 per share. | 14 Mar 2022 | 6,577 | 16,704 (0%) | 0% | 69.2 | 455,096 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 6,939 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 6,939 | 24,489 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 4,868 | 4,868 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 4,500 | 23,281 (0%) | 0% | 68.4 | 307,890 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 3,292 | 27,781 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 3,245 | 3,245 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 1,156 | 1,158 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 1,156 | 16,101 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 1,154 | 3,465 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 1,154 | 17,885 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 1,141 | 2,282 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 1,141 | 17,048 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 683 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 683 | 15,181 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 545 | 15,907 (0%) | 0% | 68.4 | 37,289 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 468 | 16,731 (0%) | 0% | 68.4 | 32,021 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 464 | 17,550 (0%) | 0% | 68.4 | 31,747 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 351 | 16,452 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 246 | 14,945 (0%) | 0% | 68.4 | 16,831 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 151 | 17,199 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 129 | 18,014 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 10 | 15,191 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 1,069 | 15,045 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 1,069 | 2,139 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.56 per share. | 01 Jul 2021 | 547 | 14,498 (0%) | 0% | 66.6 | 36,408 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 6,928 | 6,928 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 4,619 | 4,619 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 4,093 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 4,093 | 14,717 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 1,538 | 13,976 (0%) | 0% | 60.9 | 93,710 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 1,156 | 2,314 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 1,156 | 10,053 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 1,141 | 3,423 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 1,141 | 10,968 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 797 | 15,514 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 682 | 683 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 682 | 9,152 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 426 | 9,827 (0%) | 0% | 60.9 | 25,956 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 411 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 411 | 8,581 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 365 | 10,624 (0%) | 0% | 60.9 | 22,239 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 200 | 10,253 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 195 | 8,897 (0%) | 0% | 60.9 | 11,881 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 138 | 8,470 (0%) | 0% | 60.9 | 8,408 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 60 | 9,092 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 27 | 8,608 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 21 | 10,989 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 642 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 642 | 8,390 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Karen Murphy Santiago | SVP & Controller | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.97 per share. | 01 Sep 2020 | 220 | 8,170 (0%) | 0% | 61.0 | 13,413 | Common Stock, $0.10 par value |